Navigation Links
EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in,Preclinical Models

ated, "We continue to make good progress on our tubulin inhibitor program. The results of these studies will help us to further identify a lead molecule for evaluation in additional tumor models. ENMD-1420 and multiple compounds of a similar class are licensed exclusively from Celgene Corporation for development in oncology. These compounds have proven to be potent inhibitors of tumor growth and have both antiproliferative and antiangiogenic activities. We continue to evaluate ENMD-1420 and related compounds with the goal of identifying a lead molecule within the next twelve months."

To view the poster presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at www.entremed.com.

About Tubulin Inhibitors

Tubulins are the proteins that form microtubules, which are key components of the cellular cytoskeleton (structural network). Microtubules are necessary for cell division (mitosis), cell structure, transport, signaling and motility. Given their primary role in cell division, microtubules have been an important target for anticancer drugs -- often referred to as tubulin inhibitors or microtubule targeting agents. These compounds bind to tubulin protein, either in the monomer form or polymerized in microtubules, and prevent cancer cell proliferation by interfering with the microtubule dynamics required for cell division. This interference blocks the cell cycle sequence, leading to cell death (apoptosis).

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
(Date:8/29/2014)... 29, 2014 According to ... & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), ... QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global ... Oligonucleotide Synthesis Market is expected to reach $1,712.1 ... growing at a CAGR of 9.8% from 2014 ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
(Date:8/29/2014)... 2014 Research and Markets has ... Drugs Market 2014-2018" report to their offering. ... condition that results in demyelination, axonal transection, and neurodegeneration. ... response by the immune system, which targets neurons within ... debilitating disease in which the damage of the myelin ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... , MOUNTAIN VIEW, Calif. , Jan. ... system solutions to acute healthcare facilities, today announced results for its fourth ... results: Revenue for the fourth quarter of 2009 was $54.7 ... quarter of 2009, and down $7.4 million or 11.9% from ...
... , ORLANDO, Fla. , Jan. 28 ... advisor Hal Broxmeyer , Ph.D., on becoming the 2010 President ... President of such an important organization as ASH is a tremendous ... work that Dr. Broxmeyer has performed, and we are deeply honored ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 2CORD:USE Cord Blood Bank Congratulates Team Member Hal Broxmeyer, Ph.D., on his Election as President of the American Society of Hematology 3
(Date:8/30/2014)... plant-based medication commonly used to treat gout, before ... reducing potential complications from this type of surgery, ... adverse effects, according to a study published by ... early online to coincide with its presentation at ... complications after cardiac surgery include postpericardiotomy syndrome (the ...
(Date:8/30/2014)... 30, 2014 "My niece developed a ... at any moment, her fever might get worse," said ... me well aware of how she was doing, I ... ALARM to continuously monitor a child's temperature. The unit ... This ensures that prompt medical care can be given, ...
(Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
(Date:8/30/2014)... "I had a handicapped friend who could not walk along ... Wetumpka, Ala. "In order to help her be able to ... up with a way for her to use her crutches ... patent-pending Deezers to allow crutches to be used on uneven ... or canes at the beach. The device reduces the risk ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... that are not often discussed like cross-dressing, homosexuality and ... international film festival on gender and sexuality, which attracted ... ,Brought together by the Public Service Broadcasting ... and UNESCO, the four-day festival at the India Habitat ...
... Love revealed that she chants as she decides what to ... ,Chanting is used by many Buddhists celebrities including Tina ... ,Love reportedly wrote on her website: "I chanted two ... go." ,She is deciding between having a private ...
... Spanish Wine Fair (Fenavin) here, India has said it ... in production if a strong element of "price sensitivity" ... necessarily mean selling the cheapest wine," Subhash Arora, president ... three-day fair Wednesday. ,India already has a ...
... at least six years away for talented actress Kangana Ranaut but ... she wants in Mr.Right! ,"I'm going to get ... years to find Mr. Right," Kangana told IANS. ... has to be a white-collar professional like a doctor or a ...
... to have found a treatment, which could block the action ... cancer. ,The enzyme PTP1B appears to fuel tumor ... in treating the disease. About 40 percent of human breast ... this enzyme. ,Michel Tremblay and colleagues at McGill ...
... school bullying has decided to give more power to school ... ,The Prime Minister will announce this move at a meet ... ,Yet, critics of the Prime Minister like the ... this is nothing new. ,New South Wales Education ...
Cached Medicine News:Health News:Film Festival on Gender Sexuality Draws Crowds 2Health News:India is Uncorking Its Wine Market: Expert 2Health News:Gentle, Real, Well-mannered - Kangana's Mr. Right 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: